In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback